Showing results (361-370 of 439) with videos related to

Sort By:
Pageof 44
Metabolism Open|January 2, 2023
AM-879, a PPARy non-agonist and Ser273 phosphorylation blocker, promotes insulin sensitivity without adverse effects in miceM F Terra, M García-Arévalo, T M Avelino, et al.
Metabolism Open|December 5, 2022
Knowledge of cardiovascular disease risk factors, practice, and barriers of community pharmacists on cardiovascular disease prevention in North West EthiopiaMequanent Kassa Birarra, Ermiyas Baye, Worku Tesfa, et al.
Metabolism Open|December 28, 2020
Factors affecting self-medication practices among people living with type 2 diabetes in India- A systematic reviewRahul Krishna Puvvada, Sabrina Gupta, Clarice Y Tang, et al.
Metabolism Open|June 28, 2021
Vaccine induced thrombotic thrombocytopenia: The shady chapter of a success storyDimitrios Tsilingiris, Natalia G Vallianou, Irene Karampela, et al.
Metabolism Open|June 2, 2022
A comparative evaluation of cardiac and neurological safety status of two commonly used oral hypoglycaemic agents in T2-DM Swiss albino mice modelMd Ohidur Rahman, Shaheen Ahmed, Tanoy Mazumder, et al.
Metabolism Open|June 2, 2022
In-vitro antibacterial activity of commercially available probiotics on food-borne pathogens along with their synergistic effects with synthetic drugsMrityunjoy Acharjee, Fhamida Hasan, Tamanna Islam, et al.
Metabolism Open|April 5, 2021
Sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus without established cardiovascular disease: Do they have a role in primary prevention?Shailaja Kale, Abd A Tahrani
Metabolism Open|August 20, 2020
Isoorientin ameliorates lipid accumulation by regulating fat browning in palmitate-exposed 3T3-L1 adipocytesSithandiwe E Mazibuko-Mbeje, Khanyisani Ziqubu, Phiwayinkosi V Dludla, et al.
Metabolism Open|August 20, 2020
Reproducibility of a prediabetes classification in a contemporary populationChhavi Chadha, Anastassios G Pittas, Christine W Lary, et al.
Metabolism Open|August 20, 2020
A pilot study of the feasibility of empagliflozin in recent-onset type 1 diabetesJohn M Wentworth, Spiros Fourlanos, Peter G Colman, et al.
Pageof 44